MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

119.75
+2.32
+1.98%
After Hours: 119.00 -0.75 -0.63% 16:21 07/28 EDT
OPEN
117.48
PREV CLOSE
117.43
HIGH
121.40
LOW
116.01
VOLUME
851.02K
TURNOVER
--
52 WEEK HIGH
220.20
52 WEEK LOW
76.71
MARKET CAP
9.07B
P/E (TTM)
-21.2915
1D
5D
1M
3M
1Y
5Y
Griffin Asset Management, Inc. Buys Nano X Imaging, ViacomCBS Inc, Oracle Corp, Sells PepsiCo ...
GuruFocus News · 9h ago
Crispr Therapeutics Represents the Best of Emerging Biotechnology
Investor Place · 2d ago
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.
Zacks · 5d ago
Insider at CRISPR Therapeutics (CRSP) Makes Significant Sale of Stock
MT Newswires · 5d ago
Crispr Therapeutics Has Bullish DNA
Investor Place · 6d ago
Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells ...
GuruFocus News · 07/21 18:38
Insider Trends: Insider Sales Continue 90-Day Trend at CRISPR Therapeutics
MT Newswires · 07/21 17:35
Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
Benzinga · 07/21 15:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRSP. Analyze the recent business situations of Crispr Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRSP stock price target is 163.11 with a high estimate of 220.00 and a low estimate of 117.00.
EPS
Institutional Holdings
Institutions: 519
Institutional Holdings: 45.39M
% Owned: 59.91%
Shares Outstanding: 75.77M
TypeInstitutionsShares
Increased
171
4.38M
New
106
1.00M
Decreased
91
8.72M
Sold Out
72
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.50%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Chairman/President/Co-Founder/Director
Rodger Novak
Chief Executive Officer/Director
Samarth Kulkarni
Chief Financial Officer
Michael Tomsicek
Chief Operating Officer
Lawrence Klein
Executive Vice President
Tony Ho
General Counsel/Secretary
James Kasinger
Other
Philippe Drouet
Independent Director
Ali Behbahani
Independent Director
Bradley Bolzon
Independent Director
Simeon George
Independent Director
John Greene
Independent Director
Katherine High
Independent Director
Douglas Treco
No Data
  • All
  • Financials
  • Insiders
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Webull offers kinds of Crispr Therapeutics AG stock information, including NASDAQ:CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.